about
Initial genome sequencing and analysis of multiple myelomaAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeTrends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.Salvage second hematopoietic cell transplantation in myelomaSecond primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaConflicts of interest, authorship, and disclosures in industry-related scientific publications.Monoclonal gammopathy of undetermined significance: a consensus statement.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialGeriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneSingle-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyInhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.Monoclonal antibodies in the treatment of multiple myeloma.Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
P50
Q24629117-C5AF3225-0439-4C9B-9E8C-39A7CA6DD3F8Q26782868-87C085EA-345E-4398-BF69-93875193B397Q30409713-068E9DA7-17C9-4E9E-96A3-0A9C33EF9B09Q30416452-35528237-53D0-4B28-A1EA-F04CCD30A42FQ30756778-243BFFF4-E00F-4273-B456-CD4AC2DE93B5Q33367821-68D9466B-A693-4A13-8D67-615B6F2A8481Q33374964-859784B2-DFE7-4645-AA07-FC6B1A6D9F0FQ33380816-6D92A040-499A-4D12-9AF4-1D1B422E6C8FQ33389111-C6B1C2BE-2B56-49A8-A08B-B250916D5054Q33410481-D1F30554-EE9C-4DAF-B67F-D2230B13C3A7Q33412684-A2CEE4D9-E9C9-439F-B32F-8285555930FCQ33620440-9E837B4C-C728-4E7F-860E-058FCB80303DQ34117717-1BE4101E-6F8B-4FC5-A6A5-40E50B64B6F5Q34450381-A8961366-48B7-4D8E-815E-A032C2D7FA2DQ34603644-ABCDFF62-E3DB-42A0-ACBE-7271CFAFEE70Q35125893-FD1A4AA3-287C-4567-A483-DF8F91939AFDQ35220639-9DBF529D-6A09-4AC9-8770-DF49897890F9Q35802414-790FCB88-78F2-4B71-96A4-B0FC890CD34FQ36839385-040066A1-DD8C-46FF-9907-DB8705231AA3Q37037265-7D81CF8A-92B7-4D59-BB60-5A281D0CBE72Q37132862-B773C7F5-4E98-4F45-8AA8-4AEF4190E4E8Q37280739-E1A0C200-EA7E-4F7F-B31E-686374AB6F02Q37533983-D998AEC0-853D-435B-A2E8-A91273CBE29FQ37655019-CC36B924-98F0-424F-A9DB-BD943A43A215Q37827173-13DFA8ED-A33A-4FF6-891B-1CA0D2AEE962Q37835571-59AD95E9-3DE7-4A80-AB87-7E694F97D88BQ37903377-11119F64-12C1-4F06-B25F-8B70A131A510Q38234407-9BAC7C34-BA6A-48F2-BDBA-D80F87EE6E6AQ38665985-FD90125C-C2D5-47E3-94DE-30100A128711Q38693312-F70B418F-FEA1-46C2-9362-DEC5770B50B5Q38832525-B6AE5D23-FFD6-487A-B1E7-C9B8AEE2E033Q39214847-10FA837C-586D-42DF-A87A-A22D5F66187BQ40190252-0CFF65AB-99E8-4212-AE21-38C59B60C428Q40597341-2E30DF6A-E1C6-4679-BAED-185077A3CB60Q41700620-3D760AE8-5BCC-46A0-A1E4-D1F2E38FF3C9Q41867768-DD5558B9-D902-4D72-9196-FF531D8FC367Q44442859-71B5AFFC-4677-4BC4-A5E1-4FF4E482D5BFQ46423653-91277FDB-A9F9-4C0F-BEE2-E224232E08C2Q46549268-F912DCB1-900E-4394-A974-7664CB8D298D